Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: A randomized controlled trial

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Kasanmoentalib, E Soemirien ^a   Valls Seron, Mercedes ^a   Morgan, B Paul ^b   Brouwer, Matthijs C ^a   van de Beek, Diederik ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Animal models; Complement component C5; Dexamethasone; Monoclonal antibody; Pneumococcal meningitis; Randomized controlled trial

Indexed keywords

CEFTRIAXONE; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5 ANTIBODY; DEXAMETHASONE; PLACEBO; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; MALE; MORTALITY; MOUSE; NONHUMAN; PNEUMOCOCCAL MENINGITIS; PROSPECTIVE STUDY; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; TREATMENT OUTCOME; ANIMAL; C57BL MOUSE; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MENINGITIS, PNEUMOCOCCAL; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COMPLEMENT C5; DEXAMETHASONE; INJECTIONS, INTRAPERITONEAL; MALE; MENINGITIS, PNEUMOCOCCAL; MICE; MICE, INBRED C57BL; SURVIVAL;

EID: 84939148328     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0372-y     Document Type: Article

References (22)

1. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351:1849-59.
2. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev. 2011;24:557-91.
3. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2013;6, CD004405.
4. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347:1549-56.
5. Woehrl B, Brouwer MC, Murr C, Heckenberg SG, Baas F, Pfister HW, et al. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest. 2011;121:3943-53.
6. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23:467-92.
7. van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet. 2012;380:1693-702.
8. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490:187-91.
9. Brouwer MC, Heckenberg SG, de Gans J, Spanjaard L, Reitsma JB, van de Beek D. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology. 2010;75:1533-9.
10. Mook-Kanamori B, Geldhoff M, Troost D, van der Poll T, van de Beek D. Characterization of a pneumococcal meningitis mouse model. BMC Infect Dis. 2012;12:71.
11. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169-81.
12. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes Jr D, O'Neill WW, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007;297:43-51.
13. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-43.
14. Smith PK, Shernan SK, Chen JC, Carrier M, Verrier ED, Adams PX, et al. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg. 2011;142:89-98.
15. Chaudhuri A. Adjunctive dexamethasone treatment in acute bacterial meningitis. Lancet Neurol. 2004;3:54-62.
16. van de Beek D, Weisfelt M, de Gans J, Tunkel AR, Wijdicks EF. Drug insight: adjunctive therapies in adults with bacterial meningitis. Nat Clin Pract Neurol. 2006;2:504-16.
17. van de Beek D, Farrar JJ, de Gans J, Mai NT, Molyneux EM, Peltola H, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol. 2010;9:254-63.
18. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267-84.
19. Fitch MT, van de Beek D. Drug insight: steroids in CNS infectious diseases-new indications for an old therapy. Nat Clin Pract Neurol. 2008;4:97-104.
20. Imöhl M, Möller J, Reinert RR, Perniciaro S, van der Linden M, Aktas O. Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany. BMC Infect Dis. 2015;15:61.
21. Heckenberg SG, Brouwer MC, van der Ende A, van de Beek D. Adjunctive dexamethasone in adults with meningococcal meningitis. Neurology. 2012;79:1563-9.
22. Mook-Kanamori BB, Brouwer MC, Geldhoff M, van der Ende A, van de Beek D. Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis. J Infect. 2014;68:542-7.